Cancer drug cocktail shows promise for uterine tumors, but trial halted early
NCT ID NCT05481645
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug combination for people with advanced endometrial cancer or uterine sarcoma who had not yet received treatment. The combination included an immunotherapy drug (TQB2450) plus chemotherapy, with or without a targeted therapy (anlotinib). The goal was to see if the drugs could shrink tumors. The trial was terminated early, so the full results are not available, but it aimed to find a better first-line option for these cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQB2450 (a drug that helps the immune system fight cancer) combined with chemotherapy, with or without anlotinib (a drug that blocks tumor blood vessel growth)
What this could lead to
If successful, this combination could offer a new first-line treatment option for advanced uterine cancers, potentially shrinking tumors and delaying progression.
What could go wrong
The trial was terminated early, so results are limited. It was a small, phase 2 study, and the benefits seen may not hold up in larger trials. Side effects from the drug combination could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, 110801, China
-
Linyi Cancer Hospital
Linyi, Shandong, 276002, China
-
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, 200090, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, 510120, China
-
Taizhou People's Hospital
Taizhou, Jiangsu, 225399, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
-
TianJin Medical University Cancer Institute & Hopspital
Tianjin, Tianjin Municipality, 300181, China
-
Yantai Yuhuangding Hospital
Yantai, Shandong, 264099, China
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430062, China